Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imreg immunoamplifier research

Executive Summary

Firm is conducting additional trials of its IMREG-1 in approximately 20-25 patients with acquired immune deficiency (AIDS) at the University of Southern California/Los Angeles and Tulane. Investigator Arthur Gottlieb reported at a recent meeting of the American Society of Clinical Investigation that an initial study of five AIDS patients showed IMREG-1 augmented the function of defection immune cells. Previous Imreg immunoamplifier studies in cancer patients have yielded similar results ("The Pink Sheet" April 30, T&G-3).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS006562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel